Biocon Limited, the India-based biopharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Roche’s Perjeta® (pertuzumab), for the treatment of HER2-positive breast cancer. The approval, announced November 16, 2026, signifies Biocon’s continued expansion into the U.S. oncology market and its commitment to providing more affordable biologic alternatives for cancer patients.
Pebrilzo is indicated for use in combination with trastuzumab and chemotherapy for both metastatic and early-stage HER2-positive breast cancer. By mimicking the original biologic’s mechanism of action—targeting and blocking the HER2 receptor, known to fuel aggressive breast cancer cells—Pebrilzo is poised to become a new therapeutic option once it enters the market. HER2-positive subtypes account for roughly one in five of the 320,000 women projected to be diagnosed with breast cancer in the U.S. this year.
The FDA’s decision follows a September 2026 recommendation for European approval, positioning Pebrilzo for launches on both sides of the Atlantic. In the United States, however, Biocon’s settlement with Genentech, a subsidiary of Roche, establishes the earliest date for commercial launch as the third quarter of 2028, while European patients could see the drug available as early as the first quarter of 2027. These timelines reflect the complex patent and licensing environment that often shapes biosimilar entry into major markets.
Pebrilzo joins four other FDA-approved oncology biosimilars in Biocon’s American portfolio, including versions of trastuzumab, bevacizumab, pegfilgrastim, and denosumab. The new approval adds competitive pressure to Roche’s Perjeta franchise and has drawn close scrutiny from investors, with Biocon’s stock among those highlighted in the wake of the news, according to financial reporting from ad-hoc-news.de.
Like Perjeta, Pebrilzo comes with important safety warnings, including boxed cautions for potential left ventricular dysfunction and embryo-fetal toxicity, as outlined in official labeling documents. Adverse reactions reported with this class of drugs include diarrhea, hair loss, and neutropenia, underscoring the need for medical supervision and risk management during therapy.
Financial and patient impacts of Pebrilzo’s future launch remain to be seen. While regulatory hurdles are now cleared, Biocon must still navigate the logistics of launching in a highly competitive and strictly regulated market. The anticipated arrival of Pebrilzo aligns with Biocon’s broader aim to improve access to advanced cancer therapies by developing and commercializing high-quality biosimilars worldwide.